Clinical trial
Tucatinib + Abemaciclib + Herceptin for HER2+ MBC
NCT03846583
Study timeline
Study start (estimated)2020-06-28Date precision: day
Registry last updated2020-10-23
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerunresolved
Interventions
TucatinibDRUG · verified · RxNorm: tucatinib
AbemaciclibDRUG · verified · RxNorm: abemaciclib
TrastuzumabDRUG · verified · RxNorm: trastuzumab
Sponsors & collaborators
Dana-Farber Cancer Institutelead sponsor
Eli Lilly and Companycollaborator
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03846583 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.